通用杂质的免疫性:当前的正对角方法
Anne S De Groot1, Aimee Mattei2, Benjamin Gabriel2
1EpiVax, Inc, 188 Valley Street, Suite 424, Providence, RI, USA. annied@epivax.com.
Pharmaceutical research
|March 24, 2025
概括
仿制药,包括塞马格卢提德,可节省成本. 缩写新药申请 (ANDA) 途径确保通用类药物安全有效,使用直角方法进行免疫性评估.
科学领域:
- 制药科学 制药科学
- 药物开发 药物开发
- 免疫学 免疫学 免疫学
背景情况:
- 通用药物为美国消费者提供了显著的成本节省.
- 对于 Semaglutide 等负担得起的类药物的需求增加了仿制药的开发.
- 美国食品和药物管理局 (FDA) 使用缩写新药申请 (ANDA) 途径来简化仿制药的批准.
研究的目的:
- 概述通过ANDA途径提交仿制药的要求,重点关注杂质的表征.
- 强调对仿制类药物的免疫性评估的重要性.
- 描述和比较正交方法来评估通用杂物免疫性风险.
主要方法:
- 审查FDA关于提交缩写新药申请 (ANDA) 的指导方针.
- 对杂物免疫性风险评估的正交方法的描述.
- 将这些方法与MHC相关蛋白质组 (MAPPs) 等测试进行比较.
主要成果:
- 安达路径要求严格识别和描述与工艺和产品相关的杂质.
- 建议使用正对称方法来证明仿制药和参考列表药物 (RLDs) 之间的免疫学等价性.
- 作为模型主文件,PANDA®免疫性风险评估方法已提交.
结论:
- 安达途径确保仿制药符合质量和安全标准,而不会影响疗效.
- 在证明仿制类药物的安全性和等效性方面,正交法方法至关重要.
- 像PANDA®这样的标准化方法,有助于有效审查和批准仿制类药物应用.
相关概念视频
Immunoprecipitation
5.3K
Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
5.3K
Antigens Involved in Adaptive Immunity
476
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
476
Cross-reactivity
31.0K
Overview
31.0K


